Codice QR

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients

Introduction:Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Thus, this study aimed to examine the effectiveness and saf...

Descrizione completa

Salvato in:
Autori principali: Ludan Zhang, Rui Ge, Deng Pan, Pengjie Yue, Jingwen Zhang, Renjie Bian, Xiaojing Yan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2024-05-01
Serie:Frontiers in Pharmacology
Soggetti:
myelodysplastic syndromes
chronic myelomonocytic leukemia
venetoclax
hypomethylating agents
real-world study
Accesso online:https://www.frontiersin.org/articles/10.3389/fphar.2024.1265840/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi